INFINITI KRAS Assay

  • The INFINITI KRAS Assay is CE Marked.
  • The INFINITI KRAS is designed to identify KRAS genetic mutations.
  • The INFINITI KRAS utilizes the KRAS Intellipac, KRAS Amp Mix and KRAS BioFilmChip Microarray.
  • The INFINITI KRAS Assay is automated by the INFINITI Analyzer.

Analytes Detected: 
  • Codon 12: G12A, G12C, G12D, G12F, G12R, G12S, G12V
  • Codon 13: G13A, G13C, G13D, G13R, G13S, G13V
  • Codon 61: Q61E, Q61H, Q61K, Q61L, Q61P, Q61

Features: 
  • Multiplexed determination of 19 genetic variants on one BioFilmChip Microarray
  • Customized reports
  • Load & Go automated on the INFINITI/INFINITI PLUS Analyzer.
  • Replicate determinations on a single BioFilmChip Microarray ensures quality results.

Sample Type and Volume: 
  • Uses formalin-fixed and paraffin-embedded (FFPE) tissue samples.

  • Requires 25-50ng DNA/reaction

Clinical Relevance: 
  • KRAS mutations are present in >45% of colorectal adenomas and carcinomas.
  • Common in the following cancers:
  •      Colorectal (primarily)
  •      Pancreatic
  •      Lung
  •      Gall Bladder
  •      Bile Duct
  • Mutations may indicate prognosis and drug response to Cancer therapies (anti-EGFR drugs - Cetuximab/Erbitux, Panitumumab/Vectibix, Gefitinib/Iressa, Erlotinib/Tarceva).
Clinical Utility: 
  • Identification of KRAS mutations suggests that anti-EGFR therapies will not work in most, if not all patients.
  • ASCO and other cancer organizations are recommending that all patients with metastatic colorectal cancer who are considering anti-EGFR therapies should be tested for KRAS mutation status.
References: 
  1. Kahn S, Yamamoto F, Almoguera C, Winter E, Forrester K, Jordano J, Perucho M (1987). "The c-K-ras gene and human cancer (review)". Anticancer Res. 7 (4A): 639–52. PMID 3310850. 
  2. Yamamoto F, Nakano H, Neville C, Perucho M (1985). "Structure and mechanisms of activation of c-K-ras oncogenes in human lung cancer". Prog. Med. Virol. 32: 101–14. PMID 3895297.

INFINITI KRAS Assay